Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028914 | 0.83 | PARP1 (0.60) | PARP1DRD2DRD3SIGMAR1 | |
| SCHEMBL29709485 | 0.83 | PARP1 (0.60) | PARP1DRD2DRD3SIGMAR1 | |
| SCHEMBL5072005 | 0.83 | PARP1 (0.50) | PARP1DRD4OPRK1GAADRD2 | |
| SCHEMBL6028301 | 0.82 | PARP1 (0.53) | PARP1DRD4DRD2DRD3 | |
| SCHEMBL6028177 | 0.82 | PARP1 (0.56) | PARP1 | |
| SCHEMBL5621740 | 0.80 | HTR2B (0.54) | PARP1DRD4GAAJAK2JAK1 | |
| Hydrochloric Acid SCHEMBL18797659 | 0.79 | HTR2B (0.53) | PARP1DRD4GAAJAK2JAK1 | |
| SCHEMBL6029106 | 0.79 | PARP1 (0.58) | PARP1 | |
| SCHEMBL6028492 | 0.79 | PDPK1 (0.44) | PARP1GAA | |
| SCHEMBL6028372 | 0.78 | PARP1 (0.53) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087637-B2 | Substituted indoles which are PARP inhibitors | BASF AG (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | PARP1, PARP2, PARP12 | PARP1 1/4885DRD4 1137/4885OPRK1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.